Antiplatelet and anticoagulant use after myocardial infarction (Q41046059)

26 September 2017

1 reference

title

Antiplatelet and anticoagulant use after myocardial infarction (English)

1 reference

26 September 2017

1 reference

1 reference

3

Topol EJ

1 reference

26 September 2017

Almony GT

1

1 reference

PubMed ID

8723593

26 September 2017

Lefkovits J

series ordinal

2

1 reference

26 September 2017

1 May 1996

1 reference

26 September 2017

1 reference

26 September 2017

19

1 reference

26 September 2017

5

1 reference

26 September 2017

357-365

1 reference

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

26 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Principles of platelet inhibitor therapy--where we stood in 1993

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Intracoronary prostacyclin in evolving acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Epoprostenol sodium (prostacyclin) infusion in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Pharmacology of ticlopidine: a review

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Long-term anticoagulant therapy after myocardial infarction. Final report of the Veterans Administration cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

AN ASSESSMENT OF LONG-TERM ANTICOAGULANT ADMINISTRATION AFTER CARDIAC INFARCTION. SECOND REPORT OF THE WORKING PARTY ON ANTICOAGULANT THERAPY IN CORONARY THROMBOSIS TO THE MEDICAL RESEARCH COUNCIL

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

The effect of warfarin on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation to coronary artery patency

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Selective thrombin inhibitors: the next generation of anticoagulants

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Mechanism of action of thrombin on platelets

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

The interaction of platelet factor four and glycosaminoglycans

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Heparin-associated thrombocytopenia: a comparison of three heparin preparations

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Thrombocytopenia Found Uncommonly During Heparin Therapy

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Thrombin/antithrombin-III complex level as early predictor of reocclusion after successful thrombolysis

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

https://api.crossref.org/works/10.1002%2FCLC.4960190506

1 reference

7 January 2021

Development of hirudin as an antithrombotic agent

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Antithrombin properties of C-terminus of hirudin using synthetic unsulfated N alpha-acetyl-hirudin45-65

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1002%2FCLC.4960190506

7 January 2021

Identifiers

DOI

10.1002/CLC.4960190506

1 reference

26 September 2017

1 reference

PubMed ID

8723593